JointBrex Ingredients: All Eight Panel Lines, With Amounts

An amino sugar the body already makes, and the single largest thing in this capsule at 1,000 mg of a 1,400 mg serving. It is the ingredient the whole category was built on: sold since the 1980s, tested in thousands of people, and still argued about.

The trials that made its name used 1,500 mg a day. The US government's GAIT trial randomised 1,583 adults with knee osteoarthritis to glucosamine, chondroitin, both, celecoxib or placebo and found no overall benefit for the supplements; three-year European trials of glucosamine sulfate reported a structural effect on joint-space narrowing. Both are real results and they disagree, which is why the current guidelines decline to recommend it.

This label gives two thirds of that amount. It is the only line on the panel where the comparison is close enough to be worth making.

Indian frankincense: the oleogum resin of Boswellia serrata, used in Ayurvedic practice and studied in the modern literature for its boswellic acids, which inhibit the 5-lipoxygenase enzyme in inflammatory signalling.

Of everything on this panel it has the most favourable recent evidence: a 2024 systematic review and meta-analysis of boswellia oleogum resin extracts in knee osteoarthritis, and a 2026 network meta-analysis comparing it with turmeric and with the two combined. The trials behind those used 100 to 250 mg a day of extract standardised to a stated AKBA content.

133.3 mg sits inside that range, which makes this the one line where the amount is not the problem. The problem is that the panel does not say what the extract is standardised to, so there is no way to tell whether 133.3 mg here is the same thing as 100 mg there.

A long sugar chain that holds water inside cartilage, and glucosamine's near-permanent shelf partner. A pharmacokinetic study in healthy men has followed non-animal chondroitin and its constituents into the bloodstream after an oral dose, which settles the question of whether any of it is absorbed.

The amount is where it stops settling. The Cochrane review pooled trials mostly using 800 to 1,200 mg a day and described the body of evidence as low quality; the MOVES trial paired 1,200 mg of chondroitin with 1,500 mg of glucosamine and reported non-inferiority to celecoxib at six months in people with severe knee pain.

100 mg is between a twelfth and an eighth of those amounts. Whatever the chondroitin literature shows, this label is not delivering the amount that produced it.

The rhizome of Curcuma longa, and the source of the curcuminoids that carry almost all of the research interest. A meta-analysis of randomised trials in arthritis found symptom improvement at around 1,000 mg a day of curcumin — not of turmeric root, which is only about 3% curcuminoids by weight.

Absorption is the second issue and it is well quantified: the classic human study of piperine used 2 g of curcumin with and without 20 mg of piperine and measured the difference. This panel names no absorption enhancer.

100 mg of turmeric root is therefore an order of magnitude below the studied amount even before absorption is considered. It is also worth knowing the other direction: the Drug-Induced Liver Injury Network has published ten cases of liver injury linked to turmeric supplements, at amounts far above this one.

A flavonoid, here sourced from the flower bud of the Japanese pagoda tree, Sophora japonica, which is the commercial source for most quercetin on the market. It has broad antioxidant activity in the laboratory and a thin clinical record.

The one arthritis trial worth citing gave 500 mg a day for eight weeks to women with rheumatoid arthritis and reported improvements in early-morning stiffness and pain. Rheumatoid arthritis is an autoimmune disease and not the wear-related stiffness this bottle is aimed at, so even that trial is an approximate guide.

16.7 mg is about 3% of the amount that trial used, in a different condition.

An essential sulfur-bearing amino acid. The body cannot make it, so it comes from food — eggs, fish, meat, sesame, brazil nuts. A normal day of eating supplies something on the order of a gram, which is roughly sixty times what this capsule adds.

This is the panel line most often misread, and the misreading is worth naming. The molecule with an osteoarthritis literature behind it is S-adenosylmethionine, a different compound made from methionine inside the body and studied at 600 to 1,200 mg a day. Methionine is its precursor. They are not interchangeable and nothing on this panel is S-adenosylmethionine.

No trial of plain methionine for a joint outcome exists at any amount.

Methylsulfonylmethane, an organic sulfur compound. It is on the bottle and it is not in the advertising for this product, which is the more interesting half of the sentence, because it has a better clinical record than two ingredients the advertising does name.

The pilot trial in knee osteoarthritis gave 3,000 mg twice a day for twelve weeks and reported improvements in pain and physical function. A safety and applications review puts the studied range at 1.5 to 6 grams a day and finds it well tolerated across that range.

16.7 mg is about three tenths of one per cent of the pilot trial's daily amount. Its presence on the panel is honest; its amount is a gesture.

A mixture of proteolytic enzymes from the stem of the pineapple, Ananas comosus. Like MSM it is declared on the bottle and left out of the advertising, and like MSM it has randomised human trials behind it in the exact condition this product is sold for.

A placebo-controlled pilot study and a 16-week trial scored on the WOMAC index both used 800 mg a day. A 2025 crossover trial of an oral enzyme combination containing bromelain reported reductions in systemic inflammation markers, urinary CTX-II and pain in knee osteoarthritis.

16.7 mg is about 2% of 800 mg. Enzyme activity is also usually declared in activity units rather than milligrams, and this panel gives neither.